MCKMcKesson Corporation
$938.60+36% 1Y
$938.60
$695.0052 weeks$994.59
The financials
McKesson Corporation by the numbers
McKesson Corporation (MCK) reported revenue of $105.4B in Q1 2027 (quarter ended Jun 30, 2026), up 7.7% from the same quarter a year earlier. That came with a gross margin of 3.5% and net income of $614M (0.6% of revenue). For the full year FY2026, revenue was $403.4B (+12% year on year) and net income $4.76B. Its largest segment in Q1 2027 was North American Pharmaceutical at $86.8B, 82% of the disclosed total, well ahead of Oncology And Multispecialty at 13%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q1 2027 | Q1 2026 | Change |
|---|---|---|---|
| Revenue | $105.4B | $97.8B | +7.7% |
| Gross profit | $3.69B | $3.28B | +12% |
| Operating income | $1.32B | $1.04B | +27% |
| Net income | $614M | $784M | −22% |
| Diluted EPS | $5.15 | $6.25 | −18% |
| Operating | Revenue | Share |
|---|---|---|
| North American Pharmaceutical | $86.8B | 82% |
| Oncology And Multispecialty | $14.2B | 13% |
| Medical Surgical Solutions | $2.82B | 2.7% |
| Prescription Technology Solutions | $1.57B | 1.5% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $105.38B (+517%)
Oncology And Multispecialty grew +33% year on yearMedical Surgical Solutions +4.4% year on year
Segment Latestquarter on quarteryear on year
- North American Pharmaceutical$86.77B$86.77Bquarter on quarter n/ayear on year +4.9%n/a+4.9%
- Oncology And Multispecialty$14.22B$14.22Bquarter on quarter +12%year on year +33%+12%+33%
- Medical Surgical Solutions$2.82B$2.82Bquarter on quarter -1.7%year on year +4.4%-1.7%+4.4%
- Prescription Technology Solutions$1.57B$1.57Bquarter on quarter +4.7%year on year +9.2%+4.7%+9.2%
Healthcare
Ranks #2 of 446 by RyuScore